P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
- DOI
- 10.1097/01.hs9.0000971016.44640.da
- Published
- 2023-08
- Container
- HemaSphere
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1097/01.hs9.0000971016.44640.da,
title = {P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS},
author = {Jan Bewersdorf and Helen Ajufo and Claire Harrison and Francesca Palandri and John Mascarenhas and Jeanne Palmer and Aaron T. Gerds and Jean-Jacques Kiladjian and Andrii Derkach and Karisse Roman-Torres and Sarah Buckley and Raajit K Rampal},
year = {2023},
journal = {HemaSphere},
doi = {10.1097/01.hs9.0000971016.44640.da},
url = {https://doi.org/10.1097/01.hs9.0000971016.44640.da}
}RIS
TY - JOUR TI - P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS AU - Jan Bewersdorf AU - Helen Ajufo AU - Claire Harrison AU - Francesca Palandri AU - John Mascarenhas AU - Jeanne Palmer AU - Aaron T. Gerds AU - Jean-Jacques Kiladjian AU - Andrii Derkach AU - Karisse Roman-Torres AU - Sarah Buckley AU - Raajit K Rampal PY - 2023 JO - HemaSphere DO - 10.1097/01.hs9.0000971016.44640.da UR - https://doi.org/10.1097/01.hs9.0000971016.44640.da ER -
APA
Bewersdorf, J., Ajufo, H., Harrison, C., Palandri, F., Mascarenhas, J., Palmer, J., Gerds, A. T., Kiladjian, J., Derkach, A., Roman-Torres, K., Buckley, S., & Rampal, R. K. (2023). P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS. HemaSphere. https://doi.org/10.1097/01.hs9.0000971016.44640.da
Source records
- crossref · retrieved 2026-09-26T08:03:55.699Z